You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
Development of a Caregiver Application and AI-Enabled Intelligent Assistant to Support Families and Formal Care Providers in Caring for Persons with Alzheimer's Disease and Related Dementias
SBC: Whiplash Technology, Inc. Topic: NIAPROJECT ABSTRACT Family caregivers face daunting challenges in caring for persons with Alzheimer’s disease. Currently, there is no widely available mechanism to provide real-time, context sensitive support to informal AD caregivers that can address the specific care needs of each AD patient. To address this critical gap, we developed CareVirtue, an innovative web/mobile application for family ca ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Broad Spectrum Bitter Taste Antagonists Discovery
SBC: DISCOVERYBIOMED, INC. Topic: NIDCDPrincipal Investigators for Small Business: DiscoveryBioMed, Inc. (DBM) and Monell Chemical Senses Center Project Summary Abstract Bitter taste in foods and medicines presents a barrier to overcoming global public health challenges: food insecurity, poor nutritional health, and poor compliance with medication use, particularly among children and the elderly. Sugar and salt, the mainstays to addres ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
HBI-002 to Prevent Anthracycline-Related Cardiotoxicity
SBC: Hillhurst Biopharmaceuticals, Inc. Topic: NHLBIPROJECT SUMMARY There is an urgent need for the development of approaches to prevent cardiotoxicity in cancer patients being treated with anthracyclines, an important class of drugs in the treatment of cancer (e.g. doxorubicin). Anthracycline treatment-related cardiotoxicity is a major clinical problem that severely impacts patient care and also limits dose and usage. More than a quarter of patien ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point of Care Applications
SBC: GeneCapture, Inc. Topic: CBD15C001The modern warfighter faces the constant threat of endemic infections, multi-drug resistant bacteria and Biological Warfare Agents. In order to provide accurate front-line treatment that will curtail the overuse of antibiotics, a rapid and robust molecula
STTR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense -
Development of a kit for characterization of cellular energetics in single cells in cell and tissue cultures based on the measurement of the absolute magnitude of the mitochondrial membrane potential
SBC: Gerencser, Akos Topic: R41DESCRIPTION provided by applicant Altered cellular energetics contributes to human disease in general physiological aging and chronic diseases in particular including cancer neurodegeneration ischemic heart disease and type diabetes Pathological changes affecting the individual may arise only in specific cells of a tissue and potentially in a heterogeneous manner To advance basic resea ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Optimizing HaploSeq for whole-genome phased haplotypes in biomedical applications
SBC: ARIMA GENOMICS, INC. Topic: 172DESCRIPTION provided by applicant Phenomenal advances in DNA sequencing technologies have enabled systematic identification of genetic variants in human individuals and the recent FDA marketing authorization of the first next generation genome sequencer signals the arrival of a new era of pharmacogenomics and personalized medicine Nevertheless DNA sequencing alone fails to provide complete i ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Rapid Diagnostics for Mucormycosis
SBC: VITALEX BIOSCIENCES LLC Topic: NIAIDDESCRIPTION provided by applicant Mucormycosis most commonly caused by Rhizopus oryzae is a life threatening infection that occurs in patients immunocompromised by diabetic ketoacidosis DKA neutropenia corticosteroid use and or increased serum iron Because of the rising prevalence of these risk factors the incidence of mucormycosis has risen Despite disfiguring surgery and aggressive ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Temozolomide Perillyl Alcohol Conjugate as Treatment for Recurrent Malignant Brain tumors
SBC: NEONC TECHNOLOGIES INC Topic: BTDESCRIPTION provided by applicant Glioblastoma multiforme GBM the most common and malignant of all gliomas has a median survival time of months Standard of care chemotherapy using temozolomide TMZ is effective initially but the GBM inevitably recurs and these recurrent tumors are resistant to TMZ There are currently no effective treatment options for patients with TMZ resistant ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas
SBC: NEONC TECHNOLOGIES INC Topic: 102Despite important advances in surgical techniques, imagistic modalities and computer-assisted stereotactic delivery of radiation therapy, the prognosis for patients with glioblastoma (GB) remains grim and has not significantly changed in decades. The Stupp protocol—i.e., concurrent temozolomide (TMZ) plus conformal external beam radiotherapy (EBRT) followed by adjuvant TMZ—remains the cornerst ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Lowering the Cost of Imaging for Retinal Microvasculature in Diabetic Patients
SBC: AEON IMAGING LLC Topic: WDESCRIPTION provided by applicant Recently we found extensive remodeling of the microvasculature of the retina occurring in some diabetic patients much earlier than expected This provides the potential for novel biomarkers However the equipment is too expensive for most clinics and small practices These early retinal microvascular changes cannot be seen with routine clinical examination o ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health